Medical - Devices · NYSE
当前价格
$69.13
内在价值
使用下方计算器估算
对 Boston Scientific Corporation 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Earnings Yield
2.82%
ROE (TTM)
12.5%
基于过去 12 个月的数据，BSX 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
BSX 的过去 12 个月市盈率为 可在计算器中查看。该估值指标反映投资者为 Boston Scientific Corporation 每一美元收益所支付的价格。使用 MiniValuator 的 PE 计算器进行详细分析。
BSX 是否被高估取决于将其市盈率与行业同类公司、历史均值和增长预期进行比较。高于行业平均的市盈率可能表明被高估，但高成长性公司通常有更高的市盈率。在 MiniValuator 上运行完整估值来分析。
使用市盈率对 BSX 估值：将其当前 PE 与行业平均值比较，分析 PEG 比率进行增长调整估值，查看历史 PE 区间，并通过目标 PE 乘以 EPS 估算公允价值。MiniValuator 的 PE 计算器可自动完成此分析。
BSX 的 PEG 比率为 可在计算器中查看。PEG 比率将市盈率除以盈利增长率——PEG 低于 1.0 可能表明股票相对于其增长被低估，是一个有用的辅助估值指标。
PE 市盈率提供快速的相对估值——BSX 与同类公司的比较。DCF 提供绝对估值——基于预期现金流的股票内在价值。建议同时使用两种方法进行综合估值。MiniValuator 同时提供 PE 和 DCF 计算器。
